Biotechnology News and Research

RSS

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease.

2 Sep 2015

Swecure receives US patent approval for preventive allergy treatment

Swecure, a research and development stage biotechnology company primarily focused on developing novel treatments for immunoregulatory diseases such as allergy, IBD and IBS, receives patent approval grant by the US Patent and Trademark Office. The invention relates to a use of bacterial superantigens for the prevention of allergy in children as well as a method for the prevention of inflammatory disorders.

1 Sep 2015

Gene therapy restores visual function in mouse model of LCA1

Mice lacking the protein retGC1, which is deficient in humans suffering Leber congenital amaurosis-1 (LCA1), a disorder that causes severe visual impairment beginning in infancy, received gene therapy to replace retGC1 and showed fully restored visual function that persisted for at least 6 months.

1 Sep 2015

Gene ZSCAN4 may help treat Down syndrome

For people with Down syndrome, news from Elixirgen, LLC may brighten their day. The biotechnology company, located in the Science + Technology Park at Johns Hopkins, has outlined one of the best potential therapies yet for people with Down syndrome and other chromosome disorders in a paper entitled, "Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures," published in the journal DNA Research.

31 Aug 2015

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.

31 Aug 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis today announced it received the approval from the Taiwan Food and Drug Administration (TFDA) to start phase II clinical trial for its all-oral interferon (IFN)-free regimen to treat chronic hepatitis C (CHC).

31 Aug 2015

AMRI, Saneca Pharmaceuticals collaborate to develop and market opium-derived APIs

AMRI and Saneca Pharmaceuticals, a.s. today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients, ("APIs").

31 Aug 2015

Global 'Call to Action Summit 2015' adopts DELHI DECLARATION to end preventable maternal and child deaths

The two-day global 'Call to Action Summit 2015' concluded today with Health Ministers and heads of country delegations from 22 countries adopting the DELHI DECLARATION on 'ending preventable maternal and child deaths'. The declaration was developed as an outcome of the high-level ministerial conclave held yesterday during the summit.

29 Aug 2015

Oysters play important role in persistence and transmission of norovirus

Oysters not only transmit human norovirus; they also serve as a major reservoir for these pathogens, according to research published August 28 in Applied and Environmental Microbiology, a journal of the American Society for Microbiology. "More than 80 percent of human norovirus genotypes were detected in oyster samples or oyster-related outbreaks," said corresponding author Yongjie Wang, PhD.

29 Aug 2015

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.

28 Aug 2015

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell.

28 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

26 Aug 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.

26 Aug 2015

BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company), today announced it has completed the acquisition of Cellular Research, Inc.

From BD (Becton, Dickinson and Company) 26 Aug 2015

HCMC Co-Founder Derek Muhs to present keynote speech at HOSCON Summit in New Delhi, India

Health Care Management China today announced that Co-Founder and Vice Chairman Derek Muhs will present a keynote speech at the 6th annual Hospital Construction (HOSCON) Summit in New Delhi, India from September 3-4, 2015.

25 Aug 2015

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

In response to the growing opioid crisis, several states, including Massachusetts and Rhode Island, have granted pharmacists the authority to provide naloxone rescue kits without a prescription to at-risk patients. This model of pharmacy-based naloxone (PBN) education and distribution is one of the public health strategies currently being evaluated at hundreds of pharmacies in both states to determine the impact on opioid overdose death rates.

25 Aug 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015.

25 Aug 2015

Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

Accutest Research Laboratories, a leading global Contract Research Organization (CRO), further pursues its strategic expansion into Latin America by opening offices and establishing operational presence in Brazil.

25 Aug 2015

Biotechnology News and Research

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Swecure receives US patent approval for preventive allergy treatment

Gene therapy restores visual function in mouse model of LCA1

Gene ZSCAN4 may help treat Down syndrome

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

AMRI, Saneca Pharmaceuticals collaborate to develop and market opium-derived APIs

Global 'Call to Action Summit 2015' adopts DELHI DECLARATION to end preventable maternal and child deaths

Oysters play important role in persistence and transmission of norovirus

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

BD Life Sciences completes acquisition of Cellular Research

HCMC Co-Founder Derek Muhs to present keynote speech at HOSCON Summit in New Delhi, India

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News